Physician profile
Anna Gil
NPI 1174973986
$7,078.29
in general payments reported to CMS, 2019-2025
26 companies · $619 in 2025
The $619 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,676 · 2022: $2,169 · 2023: $1,038 · 2024: $1,576 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,199.74 | 2021-2025 | Tezspire, Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $806.12 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $802.98 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $697.06 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $640.68 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $468.68 | 2021-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $321.77 | 2021-2024 | Nucala |
| Sunovion Pharmaceuticals INC. | $285.04 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $268.48 | 2021-2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $245.14 | 2021-2022 | |
| Abbvie INC. | $204.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $163.53 | 2021-2022 | |
| Abbott Laboratories | $161.11 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $156.83 | 2024-2025 | |
| Globus Medical, INC. | $142.17 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $96.79 | 2021-2022 | |
| Edwards Lifesciences Corporation | $96.39 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Nevro Corp. | $87.23 | 2024 | Senza |
| Sanofi Pasteur INC. | $54.46 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $45.14 | 2021-2022 | |
| Galderma Laboratories, L.P. | $26.86 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.80 | 2022 | |
| Astellas Pharma US INC | $22.59 | 2024 | Veozah |
| Philips North America LLC | $21.98 | 2024 | (Ck7) Extended Holter |
| Eisai INC. | $19.92 | 2021 | |
| Intercept Pharmaceuticals, INC. | $18.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.